DisclosureWe earn commission on partner links; ranking is set by our evidence-based methodology — not advertisers. Read policy
Cerebral combines therapy with medication management for anxiety and depression, useful when a combined approach is appropriate.
Legit care, but read the billing fine print first
Cerebral delivers genuinely evidence-based services: video therapy and prescription antidepressants that research shows work comparably to in-person care. It is convenient, available nationwide, and accepts major insurance. However, the company has paid millions in DOJ and FTC settlements over aggressive stimulant prescribing, deceptive cancellation practices, and improper sharing of sensitive health data, so it earns a qualified recommendation rather than a wholehearted one.
We may earn a commission if you buy through this link, at no extra cost to you. It never affects our score. How we make money
Independent third-party ratings, shown for context. Not affiliated with HealthVetted scoring.
Cerebral is a direct-to-consumer telehealth company that connects users with licensed therapists, counselors, and prescribing clinicians (nurse practitioners, physician assistants, and physicians) entirely online. Founded in 2019, it grew rapidly during the pandemic-era expansion of telehealth and became one of the most heavily advertised mental health brands in the U.S.
The mechanics are straightforward and typical of the category:
Cerebral is a *service*, not a drug or device, so the right lens for evaluating it is the same one you'd apply to any telehealth program: Is the clinical care real and licensed? Is the pricing transparent? Is your data handled responsibly? Can you actually leave when you want to? On the first question Cerebral does reasonably well; on the last three, its track record demands scrutiny, as detailed below.
Cerebral markets care for common outpatient conditions: depression, generalized anxiety, panic, insomnia, PTSD, OCD, and bipolar disorder, among others. The two core service lines are:
A key, non-obvious limitation: Cerebral does not prescribe controlled substances. That means no stimulants for ADHD (e.g., Adderall, Vyvanse), no benzodiazepines (e.g., Xanax, Ativan, Klonopin), and no controlled sleep agents. The company voluntarily stopped prescribing controlled substances to all patients in October 2022 and, as part of a later federal agreement, agreed not to prescribe them in the future (DOJ, Eastern District of New York, 2024). Treatment is therefore limited to non-controlled options — for example, SSRIs/SNRIs for depression and anxiety, or non-stimulant medications — and anyone seeking stimulant-based ADHD treatment will need a different provider.
Cerebral is subscription-based, billed monthly on a recurring (auto-renewing) basis. As advertised on the company's pricing page, the general structure is:
Cerebral states it accepts insurance from several major carriers (it has listed Aetna, Cigna, Optum/UnitedHealthcare, and Blue Cross Blue Shield plans, among others), and with in-network coverage the out-of-pocket cost per visit can drop substantially — frequently to a copay in the ballpark of $30, depending on your plan. Coverage varies widely by state, carrier, and individual policy, so verify directly with both Cerebral and your insurer before assuming a price.
Two practical caveats matter more here than the headline numbers:
This is the most important section for anyone considering Cerebral, and it's where an honest independent review departs sharply from the company's own marketing.
Cerebral uses licensed clinicians and is available nationwide, and telehealth mental health care delivered competently is a legitimate, evidence-supported model of care (more on the evidence below). However, Cerebral has been the subject of multiple federal enforcement actions:
In November 2024, Cerebral entered a non-prosecution agreement with the U.S. Attorney's Office for the Eastern District of New York and agreed to pay more than $3.6 million in connection with business practices that encouraged the unauthorized distribution of controlled substances between 2019 and 2022 (DOJ, EDNY, 2024). According to the DOJ, beginning in early 2021 Cerebral allowed providers to prescribe stimulants such as Adderall and then, starting around October 2021, instituted internal measures designed to *increase* prescribing to boost subscription retention and revenue — including an internal goal to push the ADHD stimulant prescription rate toward "100%" or "near 100%," auditing providers' prescribing practices, using financial incentives, and considering disciplinary measures for providers seen as under-prescribing. Cerebral later took remedial steps, including replacing its CEO, ending the prescription metrics, and ceasing controlled-substance prescribing entirely in October 2022.
In 2024–2025, Cerebral resolved an action with the Federal Trade Commission for more than $7 million (FTC, 2024). The FTC alleged that Cerebral disclosed the sensitive health data of roughly 3.2 million people — including names, medical and prescription histories, addresses, IP addresses, and insurance details — to third parties such as LinkedIn and TikTok via tracking tools used for advertising. The FTC also alleged that, despite promising users could "cancel anytime," Cerebral imposed a complex, multi-step cancellation process and continued charging consumers while delaying their cancellation requests. The order restricts Cerebral from using or disclosing sensitive consumer data for most advertising purposes. In May 2025, the FTC announced it had sent more than $5 million in refunds to over 40,000 affected consumers (FTC, 2025).
What this means for you: Cerebral has implemented compliance reforms and is operating under federal orders that now constrain its data and billing behavior — arguably making it *more* tightly supervised than some unscrutinized competitors. But the pattern is real and recent. If you value data privacy and want frictionless cancellation, go in with eyes open: review the current privacy policy, minimize the personal data you share beyond what's clinically necessary, and document your cancellation request (date, time, confirmation) if you decide to leave.
Setting Cerebral's corporate history aside, the underlying *modality* — video-based therapy and medication management — is well supported. Multiple randomized controlled trials and meta-analyses have found that teletherapy and telepsychiatry produce outcomes broadly comparable to in-person care for common conditions.
The evidence supports a reasonable conclusion: *how* you receive competent, evidence-based mental health care (screen vs. office) matters less than *whether* the care itself is competent and consistent. Cerebral's clinical model is therefore plausible on its merits. The harder questions are continuity (will you see the same provider over time?), thoroughness of medication monitoring, and whether the subscription incentives align with your actual clinical needs rather than retention.
Cerebral may be a reasonable fit if you:
You should probably look elsewhere if you:
Cerebral sits in a crowded field, and the right comparison depends on what you need:
Across the category, the differentiators that actually matter are: whether the service prescribes what you need, transparency of recurring billing, ease of cancellation, data-privacy posture, and provider continuity. Cerebral is mid-pack on most of these and below average on privacy and cancellation history.
Cerebral is a real, nationwide, licensed-clinician telehealth service that can competently deliver therapy and non-controlled-substance medication management for common conditions like depression, anxiety, and insomnia — and the broader evidence shows video-based mental health care works about as well as in-person care for these conditions. Pricing is roughly $60/month for medication management and up to about $365/month for combined therapy and medication, with insurance often reducing per-visit costs substantially.
The serious caveats are not clinical but corporate: Cerebral cannot prescribe controlled substances (a hard no for stimulant-based ADHD treatment), it has paid multimillion-dollar federal settlements over both controlled-substance prescribing incentives (DOJ, 2024) and the sharing of sensitive health data plus deceptive cancellation practices (FTC, 2024–2025), and it bills on an auto-renewing subscription you must actively cancel. For a convenience-driven user who needs non-controlled care, has favorable insurance, and manages the subscription carefully, Cerebral can be a sensible option. For anyone prioritizing data privacy, needing controlled medications, in crisis, or wanting guaranteed provider continuity, the better choice is a platform — or an in-network local provider — that fits those specific needs. Verify current pricing, insurance, and privacy terms directly before enrolling, and keep documentation of any cancellation.
*This review is for informational purposes only and is not medical advice. Talk with a licensed clinician about your individual situation. If you are in crisis, call or text 988 (U.S. Suicide and Crisis Lifeline) or seek emergency care.*
Cerebral is not a drug or device; it is a telehealth service that connects you to licensed providers online. After a brief intake assessment, you are matched with a therapist for video or phone sessions using evidence-based methods such as cognitive behavioral therapy (CBT), and/or a prescriber who can evaluate you and prescribe non-controlled psychiatric medications (commonly SSRIs and SNRIs) for conditions like depression and anxiety. The platform handles scheduling, secure messaging, and medication coordination, with prescriptions sent to your pharmacy or shipped. The therapeutic benefit comes from the underlying treatments and the provider relationship, not the app itself.
There are no clinical trials of Cerebral the company; the relevant evidence is for the treatments it delivers. A 2022 meta-analysis of randomized controlled trials (Giovanetti et al., Telemedicine and e-Health) found video-based psychotherapy essentially equivalent to in-person therapy for depression (Hedges g of about 0.04, i.e., no meaningful difference), with comparable dropout rates. For medication, Cipriani et al.'s 2018 Lancet network meta-analysis of 21 antidepressants found every drug studied was more effective than placebo for acute major depression, with response odds ratios ranging from about 1.37 to 2.13; the broader literature puts the average antidepressant-versus-placebo effect in the modest range (standardized mean difference roughly 0.30). So the modalities Cerebral uses are well supported, while the size of the benefit is moderate and quality depends heavily on your individual provider.
A realistic timeline of what Cerebral users typically experience. Individual results vary; this is educational, not medical advice.
You complete an online intake assessment covering your history, symptoms, and goals (most therapy users finish in about 20 minutes or less), then choose a plan: Therapy, Medication + Care Counseling, or Medication + Therapy. You pay the subscription before your first visit and review provider bios to pick a match. Note: some initial matches may be associate-level clinicians working under supervision, so you can request a reassignment if a provider isn't the right fit.
Your first video or phone appointment is typically scheduled within about a week. The provider reviews your assessment, confirms or refines a diagnosis, and sets a treatment plan. If you're on a medication plan and an Rx is appropriate, a prescription may be sent to your pharmacy after this visit. This is evaluation, not a guarantee of medication; controlled substances and some conditions are not prescribed.
Therapy clients usually begin weekly sessions and start building rapport. If you started an antidepressant (e.g., an SSRI), early side effects such as nausea, sleep changes, or jitteriness often appear in the first days to two weeks and frequently ease as your body adjusts. Mood benefits are usually not noticeable yet at this stage.
For medication, this is the typical window for a follow-up to assess response and consider a dose adjustment, since antidepressants commonly take about 4-6 weeks to show meaningful mood improvement (full effect can take longer). In therapy, many people start noticing small shifts around sessions 4-8, such as catching thought patterns faster or recovering from stress more quickly. Results vary widely by person and condition.
With consistent weekly therapy, research suggests roughly half of clients show significant improvement within about 15-20 sessions. On medication, your provider may continue adjusting the dose or switching agents if response is partial; finding the right medication can take more than one trial. Plan check-ins continue (weekly therapy, or monthly care-counselor visits on medication plans).
Most people who benefit notice progress within about six months, though deeper or lasting change can take longer and progress is rarely linear. Ongoing care shifts toward maintenance: less frequent therapy as goals are met, or stable medication management with periodic reviews. Any decision to taper or stop medication should be made with your provider, not on your own.
Therapy itself carries little physical risk, though some people feel temporary emotional discomfort discussing difficult topics. The main medical risks come from any prescribed medication. SSRIs and SNRIs commonly cause nausea, headache, insomnia or drowsiness, sexual dysfunction, and weight changes. Serious but less common risks include serotonin syndrome, and antidepressants carry an FDA boxed warning for increased suicidal thoughts and behavior in people under 25, especially early in treatment or after dose changes. Never stop an antidepressant abruptly, as this can cause withdrawal symptoms. Report worsening mood, agitation, or suicidal thoughts to your prescriber immediately, and call or text 988 in a crisis.
Starts at $85/mo from Cerebral.
As of 2026, out-of-pocket prices are roughly $175 per therapy session (with discounted bundles such as about $795 for three months of regular sessions), around $60 per month for medication management (billed about $180 per quarter, with the medication itself extra), roughly $365 per month for combined medication plus therapy, and about $325 per month for couples therapy; veterans may receive a discount. With in-network insurance (Cerebral lists partners such as Aetna, Blue Cross Blue Shield, Cigna, Optum, and UnitedHealthcare), copays average around $30 per session. Prices change frequently, so confirm current rates, your coverage, and your exact copay before starting, since some users have reported surprise charges.
Prices current as of May 29, 2026 and exclude promo codes; cash-pay and channel pricing change frequently — confirm with the pharmacy or provider.
If you want flexible online therapy or non-controlled psychiatric medication and you read the subscription terms carefully, Cerebral can be a reasonable, insurance-friendly choice. Avoid it if you need stimulant ADHD medication, prefer in-person care, or are uneasy about its past billing and data-privacy violations. Cancel in writing and confirm charges each cycle. As with any mental-health treatment, decisions about medication and therapy should be made with a licensed provider.
Cerebral is a real, operating telehealth company that uses licensed providers, and the teletherapy and antidepressants it offers are evidence-based treatments. However, it has paid multimillion-dollar DOJ and FTC settlements over past stimulant-prescribing, billing, and data-privacy practices, so use it with care, read the subscription terms, and discuss any medication decisions with your provider.
Yes. Cerebral accepts several major plans, including Aetna, Blue Cross Blue Shield, Cigna, Optum, and UnitedHealthcare, with copays that average around $30 per session. Coverage varies by plan and state, so verify your specific benefits and copay before starting, as self-pay or out-of-network rates are much higher.
Self-pay prices are roughly $175 per therapy session (or about $795 for a three-month bundle of regular sessions), around $60 per month for medication management (billed about $180 per quarter, with medication extra), about $365 per month for medication plus therapy, and about $325 per month for couples therapy. Prices change often, so confirm current rates on Cerebral's site before signing up.
No. Cerebral stopped prescribing controlled substances for most patients, including stimulants like Adderall, Vyvanse, and Ritalin, in 2022. A provider may be able to discuss non-stimulant ADHD options such as atomoxetine (Strattera) or bupropion in some states, but availability is not guaranteed.
Cerebral commonly addresses depression, anxiety, insomnia, and bipolar disorder, along with general therapy needs. Medication management typically involves non-controlled drugs such as SSRIs and SNRIs prescribed by a licensed provider. It does not treat psychiatric emergencies or active crises, which need in-person or emergency care.
Cancel through your account settings or by emailing Cerebral's cancellation address, and do so before your next billing date. Cerebral's plans renew automatically and refunds are limited, and the FTC previously penalized the company for making cancellation difficult, so keep written confirmation of your cancellation.
For depression and anxiety, research generally supports it. A 2022 meta-analysis of randomized trials found video psychotherapy essentially equivalent to in-person therapy for depression (Hedges g of about 0.04, meaning no meaningful difference), with similar dropout rates. Outcomes still depend on your individual provider, the fit, and your engagement in treatment.
Avoid Cerebral if you need stimulant ADHD medication or benzodiazepines, prefer in-person care, are under 18 (outside the limited states offering teen therapy), or are experiencing a psychiatric emergency. In a crisis, or if you are having thoughts of suicide, call or text 988 or go to an emergency room.
Affiliate link — we may earn a commission at no extra cost to you, and it never changes our rankings or score. Disclosure
Same-category options, scored on the same six-axis rubric. Higher is better.